What's Happening?
Berlin Heals Holding AG has announced positive results from its CMIC-III study, which evaluated a less invasive approach to implanting a cardiac microcurrent (CMIC) device for heart failure treatment. The study, presented at the Heart Rhythm Society's
Congress in Chicago, demonstrated significant improvements in left ventricular ejection fraction, 6-minute walk test, quality of life, and New York Heart Association class. The CMIC device, which delivers a constant electrical microcurrent to the heart, was implanted via an outpatient procedure, enhancing safety and accessibility. The study involved 52 patients and showed outcomes consistent with previous surgical implantation methods.
Why It's Important?
The CMIC-III study's findings could revolutionize heart failure treatment by offering a safer, less invasive option for patients. This approach could expand access to treatment, particularly for those who may not be candidates for traditional surgical procedures. The potential to improve cardiac function and quality of life for heart failure patients is significant, as heart failure remains a leading cause of morbidity and mortality. The study's success also paves the way for further research and development, potentially leading to broader clinical applications and market approval.
What's Next?
Berlin Heals plans to initiate Phase II of the CMIC-III study, targeting patients with mildly reduced left ventricular ejection fraction. Additionally, the company will launch the C-MIC-IV double-blind sham-controlled trial, focusing on patients with both non-ischemic and ischemic heart failure. These studies aim to increase the number of implanted patients to 122, providing critical data for the FDA IDE pivotal trial. Successful outcomes could lead to market approval and widespread adoption of the CMIC device, offering a new standard of care for heart failure patients.
